Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Main Article Content

Maria De Filippo
Martina Votto
Lucia Caminiti
Francesco Carella
Giovanna De Castro
Massimo Landi
Roberta Olcese
Ilenia Panasiti
Mario Vernich
Salvatore Barberi
Giorgio Ciprandi
Gian Luigi Marseglia


Allergen Immunotherapy, Omalizumab, IgE, Tolerance, Allergic Rhinitis, Asthma


Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT.

Abstract 187 | PDF Downloads 217 HTML Downloads 15 XML Downloads 5


1. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol. 2011;127:S1–55. 10.1016/j.jaci.2010.09.034

2. Peanut allergen powder (Palforzia). JAMA. 2020;324(2):192–3. 10.1001/jama.2020.3599

3. Caminiti L, Panasiti I, Landi M, De Filippo M, Olcese R, Ciprandi G, et al. Allergen immunotherapy in atopic dermatitis: Light and shadow in children. Pediatr Allergy Immunol. 2020;31 Suppl 26:46–48. 10.1111/pai.13390

4. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;CD001936.

5. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010(12):CD002893. 10.1002/14651858.CD002893.pub2

6. Votto M, De Filippo M, Caminiti L, Carella F, de Castro G, Landi M, et al. Eosinophilic gastrointestinal disorders and allergen immunotherapy: Lights and shadows. Pediatr Allergy Immunol. 2021;32(5):814–23. 10.1111/pai.13458

7. De Filippo M, Votto M, Caminiti L, Panasiti I, Carella F, De Castro G, et al. Safety of allergen-specific immunotherapy in children. Pediatr Allergy Immunol. 2022;33 Suppl 27:27–30. 10.1111/pai.13622

8. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008–2012: An update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract. 2014;2(2):161–7. 10.1016/j.jaip.2014.01.004

9. Ciprandi G, Marseglia GL, Tosca MA. Allergen-specific immunotherapy: An update on immunological mechanisms of action. Monaldi Arch Chest Dis. 2006;65(1):34–7. 10.4081/monaldi.2006.583

10. Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol. 2011; 127(2):502–8. 10.1016/j.jaci.2010.11.036

11. Alvaro-Lozano M, Akdis CA, Akdis M, Alviani C, Angier E, Arasi S, et al. EAACI allergen immunotherapy user’s guide. Pediatr Allergy Immunol. 2020;31 Suppl 25(Suppl 25):1–101. 10.1111/pai.13189

12. Pajno GB, Castagnoli R, Arasi S, Licari A, Caminiti L, Marseglia GL. Pediatric use of omalizumab for allergic asthma. Expert Opin Biol Ther. 2020;20(7):695–703. 10.1080/14712598.2020.1751115

13. Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S,et al. Omalizumab in children. Paediatr Drugs. 2014;16:491–502. 10.1007/s40272-014-0107-z

14. Licari A, Manti S, Marseglia A, De Filippo M, De Sando E, Foiadelli T, et al. Biologics in children with allergic diseases. Curr Pediatr Rev. 2020;16(2):140–7. 10.2174/1573396315666191029123822

15. Castagnoli R, De Filippo M, Votto M, Marseglia A, Montagna L, Marseglia GL, et al.An update on biological therapies for pediatric allergic diseases. Minerva Pediatr. 2020;72(5):364–71. 10.23736/S0026-4946.20.05993-9

16. Votto M, De Filippo M, Licari A, Marseglia A, De Amici M, Marseglia GL. Biological therapies in children and adolescents with severe uncontrolled asthma: A practical review. Biologics. 2021;15:133–42. 10.2147/BTT.S252574

17. De Filippo M, Votto M, Licari A, Pagella F, Benazzo M, Ciprandi G, et al. Novel therapeutic approaches targeting endotypes of severe airway disease. Expert Rev Respir Med. 2021;15(10):1–14. 10.1080/17476348.2021.1937132

18. Barakat L, Torres MJ, Phillips EJ, Caminati M, Chang YS, Caimmi D, et al . Biological treatments in allergy: Prescribing patterns and management of hypersensitivity reactions. J Allergy Clin Immunol Pract. 2021;9(3):1396–9. 10.1016/j.jaip.2020.10.044

19. Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: More than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018;12:1753466618810192. 10.1177/1753466618810192

20. Malipiero G, Melone G, Puggioni F, Pawankar R, Heffler E, Paoletti G. Allergen immunotherapy and biologics in-respiratory allergy: Friends or foes? Curr Opin Allergy Clin Immunol. 2021;21(1):16–23. 10.1097/ACI.0000000000000707

21. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109(2):274–80. 10.1067/mai.2002.121949

22. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117(1):134–40. 10.1016/j.jaci.2005.09.036

23. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann K-C, Sieder C, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271–9. 10.1111/j.1365-2222.2008.03121.x

24. Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010; 125:383–9. 10.1016/j.jaci.2009.11.022

25. Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann K-C, et al. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol. 2013;24(5):427–33. 10.1111/pai.12098

26. Stelmach I, Majak P, Jerzyńska J, Bojo M, Cichalewski L, Smejda K. Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: A case series from Poland. Arch Med Sci.2015;11(4):901–4. 10.5114/aoms.2015.48546

27. Lambert N, Guiddir T, Amat F, Just J. Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol. 2014;25:829–32. 10.1111/pai.12306

28. Valdesoiro-Navarrete L, León ME, Rodríguez M, Indiveri M, Ayats R, Larramona H, et al. Combination therapy of specificaeroallergens immunotherapy and omalizumab, in children with severe asthma. Allergol Immunopathol (Madr). 2022;50(2):1–6. 10.15586/aei.v50i2.469

29. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010; 21(1 Pt 2): e160–5. 10.1111/j.1399-3038.2009.00900.x

30. Har D, Lee MJ. Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma. Allergy Asthma Proc. 2019;40(1):35–40. 10.2500/aap.2019.40.4173

31. Carrier C, Demoly P, Caimmi D. Omalizumab et immunothérapie allergénique: Cas clinique et revue de la littérature [Omalizumab and allergen immunotherapy: A clinical report and review of the literature]. Rev Mal Respir. 2018;36(2):191–6. 10.1016/j.rmr.2018.03.006

32. Pfützner W, Schuppe M. Use of biologics in allergen immunotherapy. Allergol Select. 2021;5:108–18. 10.5414/ALX02206E

33. Dantzer JA, Wood RA. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy. 2018;48(3):232–40. 10.1111/cea.13084